Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Alnylam Pharmaceuticals Inc at H C Wainwright Hepatitis B Virus (HBV) Mini-Conference (Virtual) Transcript

Oct 20, 2020 / 04:30PM GMT
Release Date Price: $141.45 (+0.58%)
Patrick Ralph Trucchio
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Welcome back to our afternoon session. First we're going to start with a panel discussion with Vir Biotechnology and Alnylam Pharmaceuticals. From Alnylam we have Vasant Jadhav, VP of Research and from Vir Biotechnology we have Phil Pang, Chief Medical Officer. Thank you both for joining us today.

Questions & Answers

Patrick Ralph Trucchio
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

And I think the best place to begin is to just give us a background on Alnylam's sRNA platform, as well as, tell us about the Vir and Alnylam collaboration in HBV. How far back does this go? How closely did the R&D teams work together? And then we'll have some follow-ups from there.

Vasant Jadhav
Alnylam Pharmaceuticals, Inc. - VP of Research

Sounds good, Patrick. Hey, it's a pleasure to be here. My -- again, my name is Vasant Jadhav

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot